GA management involves identifying at-risk patients, assessing visual function, and referring for treatment when necessary.

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.0, along with a high estimate of $9.00 and a low estimate of $2.00. No alteration is ...

Age-related macular degeneration (AMD ... by administering them as eye drops to mice with induced dry AMD. The treated group exhibited retinal cell protection and significantly reduced retinal ...

A 2015 paper, published in Pathobiology of Aging and Age-related Diseases, calls zinc an "essential micronutrient for human health in general, and particularly for the elderly." The authors say ...

Retinitis pigmentosa is a rare visual disorder that affects a layer of tissue in the back of the eye known as the retina—shown ... below a layer of retinal pigment epithelium cells.

Age-related macular degeneration (AMD) has three stages: early, intermediate, and late stage. Vision loss usually happens in the last stage of AMD. However, not everyone with AMD progresses through ...

Some of these treatments include retinal gene therapy and the "port" delivery system. This article discusses some of the new treatments that are emerging to treat both wet and dry age-related macular ...

There’s a big ‘if’ though: Opthea’s two phase III trials for the debilitating wet aged-related macular degeneration (wet AMD) need to come up trumps. (Refer to item one for ‘risk factors ...